Distinguished in Teratoma of the Mediastinum

Alexey A. Tryakin

Federal State Budgetary Institution Of The Ministry Of Health Of The Russian Federation
Moscow, MOW, RU 
Distinguished in Teratoma of the Mediastinum
Federal State Budgetary Institution Of The Ministry Of Health Of The Russian Federation
Moscow, MOW, RU 
OverviewLocationsClinical Research

Overview

Alexey Tryakin practices in Moscow, Russian Federation. Mr. Tryakin is rated as a Distinguished expert by MediFind in the treatment of Teratoma of the Mediastinum. His top areas of expertise are Teratoma of the Mediastinum, Testicular Cancer, Colorectal Cancer, Orchiectomy, and Bone Marrow Transplant.

His clinical research consists of co-authoring 44 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Teratoma of the Mediastinum.

Gender
Male

Locations

Federal State Budgetary Institution of the Ministry of Health of the Russian Federation
Moscow, MOW 115478, Russian Federation
Other Locations
Ufa, BA, Russian Federation

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3

44 Total Publications

The Role of MSI Testing Methodology and Its Heterogeneity in Predicting Colorectal Cancer Immunotherapy Response.
The Role of MSI Testing Methodology and Its Heterogeneity in Predicting Colorectal Cancer Immunotherapy Response.
Journal: International journal of molecular sciences
Published: February 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Tryakin's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile